Kornimate/medical-research-clean huggingface dataset:
the antidepressant effect of right temporal low frequency rtms compared to sham

Conditions: Depressive Disorder

Summary: the aim of the present study is to compare the antidepressant effect of low frequency rtms applied over the right temporal cortex with sham stimulation.

tms complies focal stimulation of the brain through a time varying magnetic field. clinical controlled trials indicate that rtms of the dorsolateral prefrontal cortex may have an antidepressant effect and no serious side effects. several clinical controlled studies investigating the antidepressant effect of low as well as high frequency rtms of the right and left prefrontal cortex have been carried out with varying results.research on the issue suffer from small and selected study populations.there is a need for additional clinical controlled studies on larger samples and methodological investigations to clarify what is the optimal stimulus design for the treatment of depressed patients. recent research indicates that depression is associated with an increased metabolic activity of subcortical areas especially the right hippocampus of the brain. remission of depression symptoms is associated with normalisation of the described subcortical hyperactivity. low frequency rtms has shown to be associated with sustained reduction in neuronal activity. there may be an association between the activity decreasing effect of low frequency rtms and reduction in psychiatric symptoms. the investigators want to test the hypothesis that low frequency rtms of the right temporal subcortical areas (hippocampus and and the parahippocampal part of cns) may perform an antidepressant effect by normalizing the described hyperactivity of the subcortical areas in depressed patients. in addition the investigators want to test whether blood concentration of brain derived neurotropic factor( bdnf), the bdnf-genotype and saliva cortisol may be of predictive value in depressed patients.

Eligibility criteria:
inclusion criteria: * inpatients admitted to århus university hospital , risskov or outpatients from the psychiatry district centres or practising specialist in the area. * moderate - severe depression according to icd-10/ dsm-ivr * age 18-80 years * total hamilton score ( 17-items) of ≥ 18 or subscale score ≥ 9 * right handed exclusion criteria: * organic brain disease * epilepsy in growing age * metallic objects as the result of a chest or brain surgery * cardiac pacemakers * somatic diseases associated with brain dysfunction * pregnancy * suicide risk of severe degree * severe agitation or delirium * alcohol and drug dependency * ongoing electroconvulsive treatment

Keywords: depression antidepressant effect rtms sham cognition saliva cortisol brain derived neurotropic factor
prevalence of traumatic events and ptsd in immigrant and non-immigrant patients with psychotic disorder

Conditions: Psychotic Disorders; Psychological Trauma; Stress, Psychological; Cross-Cultural Comparison

Summary: higher rates of psychosis are described in migrant population. likewise, this populations could suffer several adversities during migration process that could lead to higher exposure to traumatic events and higher rates of posttraumatic stress disorder (ptsd). there is a growing evidence that trauma is associated with psychosis onset. the aim of this research is to study the association between psychosis and traumatic events exposure/ptsd in immigrant population. our hypothesis is that the higher incidence of psychosis described in immigrant population is associated to higher trauma exposure. a case-control observational study is performed. patients who presented at least one psychotic episode are recruited from acute and chronic units at "parc salut mar" (barcelona). estimated total sample is 196 individuals. trauma exposure is assessed by validated trauma scales. known factors associated with psychosis are controled during the statistic analysis.


Eligibility criteria:
inclusion criteria: * to present history of one or more psychotic episodes defined according to dsm-5 criteria, including patients with diagnoses of schizophrenia, schizoaffective disorder and non-specific psychotic disorders. * patients of non-local origins who have undergone a migration process along the life line (as case individuals) and autochthonous patients (as control individuals). * age between 18 and 65 years. exclusion criteria: * patients who have not clinical stability. * important cognitive limitations to understand informed consent nor applied questionnaires. * language barrier that limits understanding informed consent nor applied questionnaires.
therapeutic effects and long-term follow-up after ending nucleos(t)ide analogs therapy in chronic hepatitis b

Conditions: Chronic Hepatitis b

Summary: the study is to observe the therapeutic effects and long-term follow-up after ending anti-hbv therapy with nucleos(t)ide analogs in patients with chronic hepatitis b.

patients with chronic hepatitis b were enrolled in the study. age, sex, weight, height, symptoms (e.g., fatigue, poor appetite, jaundice), relapse, retreatment, occurrence of liver cirrhosis and hepatocellular carcinoma (hcc), mortality and survival rate were recorded in the study. we also observed the laboratory tests including the levels of white blood cells (wbc), red blood cells (rbc), hemoglobin (hgb), platelet (plt), alanine transaminase (alt), aspartate transaminase (ast), total bilirubin (tbil), blood urea nitrogen (bun), creatine, hepatitis b surface antigen (hbsag), hepatitis b e antigen (hbeag), hepatitis b virus (hbv) dna, cd4 positive t lymphocyte (cd4+t), cd8 positive t lymphocyte (cd8+t), type 1 helper t lymphocyte (th1), type 2 helper t lymphocyte (th2),fibroscan and b ultrasound. if clinical relapse occurred, patients were retreated with nucleos(t)ide analogs.

Eligibility criteria:
inclusion criteria: 1. patients received anti-hbv therapy with nucleos(t)ide analogs. 2. last anti-hbv therapy should continue for at least 2 years. 3. for hbeag positive patients, hbv dna should keep negative for at least 1 year after hbeag seroconversion before the therapy ending; for hbeag negative patients, hbv dna should keep negative for at least 2 years before the therapy ending. exclusion criteria: 1. liver cirrhosis, hcc; 2. patients with other factors causing active liver diseases; 3. pregnancy or lactation; 4. patients with hiv infection or congenital immune deficiency diseases; 5. patients with severe diabetes, autoimmune diseases, other important organ dysfunctions and other serious complications.

Keywords: chronic hepatitis b, nucleos(t)ide analog
evaluation of paclitaxel in patients with cli and femoropopliteal occlusive disease treated with dcb angioplasty

Conditions: Ischemia

Summary: the use of drug coated balloon (dcb) in patients with critical limb ischemia (cli) and tissue loss has recently raised some concerns after the in.pact deep trial using paclitaxel coated balloon angioplasty in the tibial arteries was terminated. the investigators objective is to establish the safety and efficacy of drug coated balloon (dcb) for femoropopliteal occlusive disease in patients with critical limb ischemia (cli) and tissue loss. the investigators objective is to establish the safety and efficacy of drug coated balloon (dcb) for femoropopliteal occlusive disease in patients with critical limb ischemia (cli) and tissue loss.

although the association between the drug coated balloon (dcb) therapy and limb outcomes could not be clearly linked to the use of antiproliferative agents, the findings of paclitaxel crystals downstream of the treated lesions, although in small amounts, has raised concerns about the safety of such therapy in patients with critical limb ischemia (cli) and tissue loss. these concerns, however, may not translate to patients with femoropopliteal occlusive disease as the amount of paclitaxel reaching the foot may be even smaller after being filtered by the calf musculature. since the use of dcb angioplasty in the superficial femoral artery (sfa) and popliteal has been shown to deliver significantly more durable outcomes compared to standard angioplasty alone, with reported primary patency rates of almost 90% at one year, this therapy may even be more needed in patients with tissue loss where prolonged patency is essential for wound healing.

Eligibility criteria:
inclusion criteria: * patient population: all patients with cli (critical limb ischemia) and tissue loss scheduled for endovascular intervention for femoral popliteal occlusive or multilevel disease. * patient or patient's legal representative have been informed of the nature of the study, agrees to participate and has signed an ethical committee approved consent form * female patients of childbearing potential have a negative pregnancy test ≤7 days before the procedure and are willing to use a reliable method of birth control for the duration of study participation * patient has documented chronic critical limb ischemia (cli) in the target limb prior to the study procedure with rutherford category 5 or 6 * general angiographic inclusion criteria * single or multiple lesions with ≥70% diameter stenosis (ds) of different lengths in the sfa and/or popliteal arteries. * iliac inflow or tibial outflow interventions can be done at the discretion of the investigator with standard balloon percutaneous transluminal angioplasty (pta) exclusion criteria: * patient unwilling or unlikely to comply with follow-up schedule * aneurysm in the target vessel * acute thrombus in the target limb * sensitivity to paclitaxel * immunosuppressed patients (transplant, chemotherapy, etc.)

Keywords: critical lower limb ischemia with tissue loss
effectiveness of yunnan baiyao in improving fracture pain

Conditions: Distal Radius Fracture

Summary: this will be a randomized, controlled, non-inferiority designed clinical trial. 56 qualified subjects will be selected and allocated 1:1 to yunnan baiyao group and celecoxib group. each subject will be treated for 2 weeks and observed for 12 weeks, which will be lasted for 14 weeks during the whole trial. yunnan baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. one capsule of baoxianzi will be provided for the first time to be taken at the same time with yunnan baiyao capsule, which will be given continuously for 2 weeks. the celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.

his will be a randomized, controlled, non-inferiority designed clinical trial. 56 qualified subjects will be selected and allocated 1:1 to yunnan baiyao group and celecoxib group. each subject will be treated for 2 weeks and observed for 12 weeks, which will be lasted for 14 weeks during the whole trial. yunnan baiyao group will be given 4 times a day, 2 capsules each time after morning, afternoon and evening meals and before going to bed. one capsule of baoxianzi will be provided for the first time to be taken at the same time with yunnan baiyao capsule, which will be given continuously for 2 weeks. the celecoxib group will be given 1 capsule twice a day after breakfast and dinner for 2 weeks.

Eligibility criteria:
inclusion criteria: 1. the age of the subject is 20-70 years old; 2. patients with distal radius fractures (colles fractures) ; 3. conservative treatment (closed reduction and fixation) after fracture; 4. willingness to participate in this study and sign the informed consent form (icf). exclusion criteria: 1. pathological fractures such as multiple fractures and cancer; 2. patients with a history of severe chronic disease, such as hypertension, coronary heart disease, diabetes, tuberculosis, etc.; 3. patients with endocrine diseases unsuitable for inclusion or other related diseases affecting bone metabolism, such as thyroid diseases of clinical significance as hyperparathyroidism, parathyrometaplasia, paget's disease, cushing's syndrome, nephrotic rickets, osteomalacia, rheumatoid arthritis, gout, multiple myeloma, osteogenesis insufficiency, etc.; 4. complicated with malignant tumor, mental illness and other diseases that doctors think may affect the test process; 5. currently using bone metabolism regulation drugs, such as teripartide, bisphosphonate, etc.; 6. had a history of chronic pain and used painkillers daily before enrollment; nonsteroidal anti-inflammatory drugs, opioids, and physical therapy for pain relief within a week after fracture; 7. pregnant and lactating women; 8. allergic to yunnan baiyao or any excipients and celecoxib, or suffering from contraindications or intolerance indicated by the test drug; 9. continuous use of antibiotics; 10. patients with coagulation dysfunction, receiving anticoagulant therapy or taking antiplatelet aggregation drugs.
effect of carbonated soft drinks on the body weight

Conditions: Obesity; Metabolic; Complications; Dietary Habits

Summary: compared to solid foods, the nutritional energy of drinks may bypass the appetite regulation leading to obesity development. although drinks sweetened with aspartame are available the anticipated positive effect of these drinks on obesity development has not been convincing. however, the mechanisms linking drinks intake to obesity are yet to be clarified. the investigators aim is to investigate the long-term effects of intake of soft drinks, milk and water. the study is a parallel, intervention trial with 80 overweight, healthy volunteers. they will be randomly selected to drink one liter a day of one of the four drinks for six months. the objectives are changes in numerous circulating metabolic risk factors, changes in body weight, anthropometric data and fat distribution (measured by dexa, mri and mr-spectroscopy). the investigators expect to clarify the mechanisms linking drinking habits to obesity development and provide scientifically based nutritional guidelines.


Eligibility criteria:
inclusion criteria: * age between 20-50 years; * bmi between 28-36 kg/m2; * weight stabile 3 months prior to the study inclusion; * less than 10 hours of weekly exercise exclusion criteria: * diabetes * allergic to phenylalanine or milk * smoking * pregnancy or breast-feeding
intrauterine insemination and luteal fase support

Conditions: Infertility

Summary: the objective is to test the hypothesis that luteal phase support with vaginal progesterone leads to a higher clinical pregnancy rate (primary outcome) and live birth rate (secondary outcome) when compared to no luteal phase support in a program of intrauterine insemination (iui) after controlled ovarian stimulation with gonadotrophins. additionally, the length of the luteal phase will be recorded (secondary outcome) in order to detect luteal phase defects/insufficiencies in the absence of luteal phase suppletion as well as luteal phase prolongation in case of luteal phase support which may be a burden for the patients waiting for the outcome of the treatment.


Eligibility criteria:
inclusion criteria: patients with an indication for iui: * unexplained infertility * mild male factor infertility * minimal-mild endometriosis women: * first iui cycle ever * normal ovulatory cycles (26-32d) * age\<43,bmi≤30 * presence of at least one patent tube on hysterosalpingography and/or laparoscopy * normal uterine cavity (ultrasound, hysterosalpingography, or laparoscopy) men: total motile count ≥ 5 million/ml after capacitation exclusion criteria: * patients with contra-indication for pregnancy , infertility or progesterone use.

Keywords: intrauterine insemination luteal phase gonadotrophins
comparison of intubation conditions between the gliderite and the s-guide

Conditions: Nasal Obstruction; Lumbar Stenosis, Familial

Summary: intubation with an unchanneled videolaryngoscope mandates the use of a stylet. the gliderite is a stylet specially designed for videolaryngoscopes. the investigators aim to compare the efficacy of a new designed bougie for intubation in patients with simulated difficult airways.

intubation with an unchanneled videolaryngoscope mandates the use of a stylet. the gliderite is a stylet specially designed for videolaryngoscopes. the investigators aim to compare the efficacy of a new designed bougie for intubation in patients with simulated difficult airways. the primary endpoint will be time necessary for intubation, secondary endpoints will be injuries, ease of use and subjective assessment.

Eligibility criteria:
inclusion criteria: * surgery necessitating general anesthesia and orotracheal intubation exclusion criteria: * history or criteria of difficult intubation * patient refusal
data aquisition for optimization of coronary artery disease algorithm

Conditions: Coronary Artery Disease

Summary: the purpose of the study is to optimize an already existing algorithm for diagnosing atherosclerosis of the coronary arteries (cad, coronary artery disease).

acoustic information from the heart is obtained from patients suffering from coronary artery disease. the acoustic signals are evaluated as indicators for cad.

Eligibility criteria:
inclusion criteria: * age minimum 18 years * referred to cag on suspicion of cad * stabile angina without acs * signed informed consent exclusion criteria: * acs * previous bypass operation * previous heart transplant(incl. mechanical or artificial) * pregnancy * damaged skin on examination location
health improvement program of bone in china

Conditions: Osteoporosis

Summary: fracture risk factors have long been identified as key factors in osteoporosis and fragility fractures. the who recommended fracture risk assessmenttool (frax) applies clinical risk factors to assess the absolute risk of osteoporotic fractures in each individual. our preliminary study suggests that frax estimates may underestimate the risk of fractures in the chinese population. in order to optimize the risk prediction model of osteoporotic fractures, a treatment threshold and its optimal cutting point were initially established based on the data of the health management center of the second xiangya hospital of central south university.


Eligibility criteria:
inclusion criteria: * dual-energy x-ray bone mineral density measurement was performed in the health management center of our hospital in the physical examination subjects over 40 years old. have independent civil capacity and agree to participate, and sign informed consent exclusion criteria: * under 40 years of age， patients who had undergone hip replacement or lumbar surgery and could not perform dual-energy x-ray bmd testing; patients who have been treated with effective anti-osteoporosis drugs or have a history of malignant tumors.
a phase 2 study of ic14 in acute respiratory distress syndrome

Conditions: Acute Respiratory Distress Syndrome

Summary: acute respiratory distress syndrome (ards) patients will be randomized to receive either ic14 (a single dose of 4 mg/kg followed by 2 mg/kg on days 2-4) or placebo. study participation will be for a total of 28 days.

up to 160 patients with ards will be randomized to receive either ic14 at a dosage of 4 mg/kg on study day 1, then 2 mg/kg once daily on study days 2-4 or placebo for 4 days beginning within 48 hours of meeting inclusion criteria. study participation will be for 28 days.

Eligibility criteria:
inclusion criteria: 1. icu admission 2. age 18-70 years 3. presence of a known ards clinical risk within 7 days of onset: 1. pneumonia 2. sepsis 3. trauma 4. aspiration 5. pancreatitis 4. presence of ards (per berlin criteria) defined as follows: 1. acute onset (\<48 hours) 2. pao2/fio2\<300 on peep≥5 3. bilateral opacities consistent with pulmonary edema on frontal chest radiograph not fully explained by effusions, lobar/lung collapse, or nodules. 4. requirement for positive pressure ventilation via endotracheal tube 5. anticipated duration of mechanical ventilation \>48 hrs exclusion criteria: 1. treatment with a drug or device within the last 30 days that has not received regulatory approval at the time of study entry 2. intubation for cardiopulmonary arrest 3. do-not-attempt resuscitation (dnar) status 4. intubation for status asthmaticus, pulmonary embolus, myocardial infarction 5. anticipated survival \<48 hours from intubation 6. anticipated survival \<28 days due to pre-existing medical condition 7. significant pre-existing organ dysfunction 1. lung: currently receiving home oxygen therapy as documented in medical record 2. heart: pre-existing congestive heart failure defined as an ejection fraction \<20% as documented in the medical record 3. renal: chronic renal failure requiring renal replacement therapy 4. liver: severe chronic liver disease defined as child-pugh class c 8. pre-existing, ongoing immunosuppression 1. solid organ transplant recipient 2. chronic high-dose corticosteroids (equivalent to \>20 mg/prednisone/day for \>14 days in the last 30 days) 3. oncolytic drug therapy within the past 14 days 4. known hiv positive with cd4 count \<200 cells/mm3 9. current treatment with enbrel® (etanercept), remicade® (infliximab), humira® (adalimumab), cimzia® (certolizumab), or simponi® (golimumab), kineret® (anakinra), or arcalyst® (rilonacept) 10. pregnancy 11. history of hypersensitivity or idiosyncratic reaction to ic14 12. deprivation of freedom by administrative or court order
combined vi vaccination and health education program on the burden of typhoid in childhood

Conditions: Typhoid; Paratyphoid Fever

Summary: this study is part of the international vaccine institute's (ivi's) typhoid vi demonstration project that aims to accelerate the rational introduction of vi vaccines in typhoid endemic countries. the purpose of this study is to determine the effectiveness of the vi vaccine following a mass typhoid immunization campaign in an endemic area in karachi, pakistan. the cost-effectiveness of vi vaccination and the logistic feasibility of a mass typhoid immunization campaign will also be evaluated.

typhoid fever is a major cause of morbidity worldwide. the disease predominantly affects school-aged children, is more prevalent in urban areas, may last for several weeks and can lead to serious complications. management of this disease is further complicated by the emergence of multi-drug resistant strains. vaccination of high risk populations is considered the most promising strategy for the control of typhoid fever. the vi polysaccharide vaccine has been targeted for accelerated introduction into public health programs due to the following reasons: it has been shown to have consistent efficacy results even in areas of high typhoid incidence; is given as a single dose; lacks patent protection and requires less strict cold chain requirements. a cluster-randomized trial involving the vi polysaccharide vaccine and an active control (hepatitis a) was designed to determine the effectiveness and the feasibility of providing vi vaccine under actual programmatic conditions in 3 urban slums in pakistan. the vaccines used in this study are internationally produced and locally licensed. a complimentary, targeted, basic typhoid prevention health education program for the entire population at the initiation of the project will be provided and the actual vi-demonstration project will be preceded by a 12-month typhoid surveillance activity. secondary objectives of this trial are: * to monitor the adverse events following a routine vi mass vaccination campaign; * to assess the knowledge, attitudes, beliefs and practices among parents and health care providers regarding typhoid illness, treatment and prevention; and * to study typhoid fever risk factors in the population. a nested, prospective matched case-control study is included in the trial in order to study typhoid risk factors among children in karachi.

Eligibility criteria:
inclusion criteria: * registered in the project census * age: 2-16 years exclusion criteria: * fever \>37.5 degrees celsius, axillary * pregnancy * lactating

Keywords: salmonellosis typhoid vaccine enteric fever